Drug maker Lupin on Wednesday said it has launched the generic version of Oracea capsules in the U.S. market. The company said it has launched the medication, indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea, following approval from the U.S. Food and Drug Administration.
As per the IQVIA MAT data, Doxycycline capsules (Oracea) had estimated annual sales of $128 million in the U.S.
Shares of the company were trading 0.77% up at Rs 1,617.35 apiece on Bombay Stock Exchange.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
